Biosimilars and Biobetters Conference 2014

This year's conference will focus on the current and future landscape of the biosimilars market and will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

KEY SPEAKERS INCLUDE:

Global Head Generics, Thought Leadership, Alan Sheppard, IMS Health

Founder, Carsten Brockmeyer, Brockmeyer Biopharma GmbH

Regulatory Affairs Manager, Catherine Akers, Amgen Inc

CEO, Ineke Braat, Pan-Generika

Partner, Liz Fuller, Bird and Bird

INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Michael Tovey, Ecole Normale Supérieure de Cachan

Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Michel Mikhail, Fresenius Kabi

Senior Consultant, Peter Wittner, Interpharm Consultancy

Chairman, Richard Dicicco, Harvest Moon Pharmaceuticals

Legal Director, Sarah Faircliffe, Bird and Bird

Principal Scientist and Head Analytical Development, Sharma Alok, Lupin Laboratories Ltd

Medical Director, Steinar Madsen, Norwegian Medicines Agency

Head of Safety Biosimilars, Uwe Gudat, Merck Switzerland Limited

Managing Director, Victoria Fine, PSORIASENSE